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Abstract
Background: Microvascular permeability and leukocyte adhesion are pivotal mechanisms in sepsis pathophysiology
contributing to the development of shock and mortality. No effective pharmacological therapy is currently available
to restore microvascular barrier function in sepsis. Cholinergic mediators have been demonstrated to exert
anti-inflammatory effects during inflammation. Cytidine-5-diphosphocholine (CDP-choline) is an extensively studied
cholinergic drug due to its brain protective characteristics in cerebrovascular diseases. This study evaluated the
effect of CDP-choline on microvascular permeability and leukocyte adhesion during endotoxemia.
Methods: Macromolecular leakage, leukocyte adhesion, and venular wall shear rate were examined in mesenteric
postcapillary venules of rats by using intravital microscopy (IVM). Lipopolysaccharide (LPS) (4 mg/kg/h) or equivalent
volumes of saline were continuously infused following baseline IVM at 0 min. IVM was repeated after 60 and
120 min in endotoxemic and nonendotoxemic animals. CDP-choline (100 mg/kg) was applied as an i.v. bolus.
Animals received either saline alone, CDP-choline alone, CDP-choline 10 min before or 30 min after LPS administration,
or LPS alone. Due to nonparametric data distribution, Wilcoxon test and Dunn's multiple comparisons test were used
for data analysis. Data were considered statistically significant at p < 0.05.
Results: Treatment with LPS alone significantly increased microvascular permeability and leukocyte adhesion and
decreased venular wall shear rate. CDP-choline significantly reduced microvascular permeability in animals treated with
LPS. Leukocyte adhesion and venular wall shear rate were not affected by CDP-choline during endotoxemia.
Conclusion: CDP-choline has a protective effect on microvascular barrier function during endotoxemia. Considering
the excellent pharmacologic safety profile of CDP-choline, its use could be an approach for the treatment of
capillary leakage in sepsis.
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Background
Sepsis is a serious problem in critical care medicine with
significant mortality [1] directly associated to micro-
circulatory alterations [2]. Microcirculatory alterations
are early indicators of tissue injury prior to septic organ
failure, characterized by the functional breakdown of
microvascular perfusion with concomitant tissue edema
formation. Progressive edema formation due to increased
endothelial permeability leads to impaired tissue oxygen-
ation, which precedes organ damage and shock in sepsis.
Inflammatory endothelial cell activation and leukocyte-
endothelial interactions can be positively influenced by
cholinergic mediators [3, 4]. This beneficial cholinergic
anti-inflammatory effect on endothelial function can be
attributed to the activation of anti-inflammatory neuro-
immunological mechanisms described by Tracey et al.
[5, 6]. The inflammatory reflex and the cholinergic
anti-inflammatory pathway (CAP) modulate the magni-
tude of the innate immune response by limiting pro-
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inflammatory processes to a non-toxic range, thereby
minimizing tissue injury [5, 6]. CAP-mediated anti-
inflammatory signals result in the release of acetylcholine
(ACh), which interacts with innate immune cells that ex-
press the nicotinic acetylcholine receptor subunit α7
(α7nAChR). Intracellular α7nAChR signal transduction
inhibits the transcription of pro-inflammatory genes [5, 6].
Human and rat endothelial cells express α7nAChR, identi-
fying the endothelium as a target for anti-inflammatory
cholinergic mediators [3, 7].
Cytidine-5-diphosphocholine (CDP-choline) has been
studied for its brain protective properties in cerebrovascu-
lar and neurodegenerative diseases in several clinical trials,
and has shown an excellent drug safety profile [8–10].
Locally administered CDP-choline reduced TNF alpha
production and tissue edema in a carrageenan-induced
inflammatory pain model dependent on the presence of
inflammation and non-neuronal α7nAChR [11]. We
hypothesized that CDP-choline could reverse sepsis-
induced microcirculatory alterations. Therefore this study
determined the effects of CDP-choline on microvascular
permeability and leukocyte-endothelial interactions during
experimental endotoxemia.
Methods
The general aspects of the materials and methods
used have been described in detail in previous publi-
cations [4, 12].
Anesthesia and animal preparation
The Governmental Animal Protection Committee ap-
proved the experimental protocol used in this investi-
gation (project licence number 35–9185.81/G-123/10).
Male Wistar rats (n = 39, randomized to study groups,
250–300 g body weight; Janvier; St Berthevin, France)
were maintained in an animal facility with a 12-h light–
dark cycle and housed in stainless steel cages in a
temperature-and humidity-controlled room. Standard
diet and water were available ad libitum.
Anesthesia was induced with 60 mg/kg pentobarbital
i.p. (Narcoren®, Merial GmbH, Hallbergmoos, Germany).
Anesthesia was maintained with repeated injections of
10 mg/kg pentobarbital i.v.. The left carotid artery was
cannulated for continuous real time monitoring of mean
arterial pressure (MAP [mmHg]) and heart rate (HR
[min−1]) using a computerized non-commercial small
animal monitoring system (Small Animal Monitoring Vs.
1.2.6.3, Exp. Chirurgie, Heidelberg 2012). The right
jugular vein was cannulated for administrating test sub-
stances. Temperature was measured with a rectal ther-
mistor probe and maintained at 37 °C. A segment of the
ileum was gently exteriorized through a mid-line ab-
dominal incision and draped over a clear glass pedestal
for intravital microscopy examination. Exposed tissues
were continuously superfused with buffered (pH 7.4) and
thermostat-controlled Ringer solution (37 °C).
A stock solution of LPS (Lipopolysaccharide, Escherichia
coli 026:B6, Sigma-Aldrich Chemie GmbH, Steinheim,
Germany) was prepared by dissolving LPS in saline to a
concentration of 5 mg/ml. The solution was stored in a
glass container at 5 °C. The stock solution was diluted in
saline to the appropriate concentration for experiments.
Infusions of LPS (4 mg/kg/h) or equivalent volumes of
saline solution were administered via the jugular vein. The
LPS dosage of 4 mg/kg/h was identified in pilot experi-
ments as the LPS dosage without pronounced hypotension
and a significant inflammatory endothelial activation
(macromolecular leakage, leukocyte-endothelial interac-
tions) compared to nonendotoxemic animals.
Cytidine-5-diphosphocholine (CDP-choline, Sigma-
Aldrich Chemie GmbH, Steinheim, Germany) was diluted
in saline to the appropriate concentration for each rat and
was injected i.v. according to the experimental protocol
(Fig. 1).
For measurement of erythrocyte velocity fluorescent-
labeled erythrocytes from donor rats were injected
10 min before baseline measurements (0.5 mL/kg body
weight; hematocrit 50 %; labeled with a red fluorescent
cell linker kit (PKH26-GL; Sigma Chemical, Deisenhofen,
Deisenhofen, Germany).
To quantify albumin leakage across mesenteric ve-
nules, 50 mg/kg of fluorescein isothiocyanate-labeled
bovine albumin (FITC-albumin; Sigma Chemicals,
Deisenhofen, Germany) was injected 10 min before base-
line measurements.
Intravital microscopy
Intravital fluorescence microscopy (IVM) was performed
at 0, 60, and 120 min (Fig. 1). Selected post-capillary ve-
nules were observed with a specially designed micro-
scope (Orthoplan, Leica, Wetzlar, Germany) equipped
with a 40-fold water immersion objective (Achroplan
40/0.75 W; Zeiss, Jena, Germany).
Images were recorded and digitized with a digital
camera (TypPS/DX4-285FW, Kappa opto-electronics
GmbH, Gleichen, Germany) equipped with a captur-
ing software (Streampix 5.3.0, Norpix Inc., Montreal,
Canada).
ImageJ (NIH, Bethesda, MD) and Histo (Histo, Version
3.0.2.4, Exp. Chirurgie, Uniklinik Heidelberg 2011) were
used for offline image analysis.
The analysis software was calibrated to the afore-
mentioned microscope/camera setting yielding a pixel
spacing of 3.25 pixel/μm in effective magnification. A
fluorescence gray scale from black to white (gray levels
ranging from 0 [black] to 255 [white]) with fixed bright-
ness and contrast levels was used for recording and
analysis.
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Quantification of macromolecular leakage
The recorded fluorescent images were digitized and the
gray levels reflecting fluorescent intensity were measured
within the venule under study (iv) as well as in an equal
and contiguous area of the perivenular interstitium (ii).
Macromolecular leakage was determined as ii/iv ratio
(arbitrary units).
Leukocyte-endothelial interactions
The behavior of leukocytes was visualized using transillu-
mination microscopy. Adherent leukocytes were defined
as cells that did not move or detach from the endothelial
wall for a period of 30 sec and were counted offline during
playback of the recorded videos. Leukocyte adherence was
expressed as the number of cells per square millimetre of
vessel surface as calculated from the diameter and length
of the vessel segment studied.
Measurement of venular wall shear rate
Mean red blood cell velocities (VRBC) in single un-
branched post-capillary venules were calculated by aver-
aging the velocities of 20–30 individual erythrocytes.
The distance through which a labeled erythrocyte trav-
elled within two subsequent video frames was divided by
the video frame time interval. Venular wall shear rate
was calculated on the basis of the Newtonian definition
(γ =8 (VRBC/Dv)), using the measured vessel diameters
of the observed postcapillary venules.
Experimental protocol
The experimental protocol is illustrated in Fig. 1. The
color code of the experimental groups introduced in Fig. 1
is used in the results section for Fig. 2 and Fig. 4 as well.
Anaesthesia and surgical preparation was identical for
all animals. A 45-min stabilization period followed ex-
teriorization of the mesentery. Animals were randomized
to the respective treatment groups 10 min before base-
line intravital microscopic measurements (IVM) at
0 min. IVM were performed at 0, 60, and 120 min in
endotoxemic and nonendotoxemic animals. Macrohe-
modynamic parameters (single values; MAP and HR)
were documented at these time points. LPS (4 mg/kg/h)
or an equivalent volume of saline was continuously
infused starting directly after baseline IVM at 0 min.
CDP-choline (100 mg/kg) was applied as an i.v. bolus in
treatment groups. All administered fluids were calculated
to guarantee that all animals received equal amounts of
intravenous fluids.
After randomization animals [n = 39] received saline
alone in the NaCl (i) [n = 8] group, CDP-choline 10 min
prior to saline infusion (ii) [n = 6], CDP-choline 10 min
prior to LPS administration (iii) [n = 8], CDP-choline
30 min after LPS administration (iv) [n = 9], and LPS alone
(v) [n = 8] in the endotoxemia group.
At baseline IVM inclusion criteria for postcapillary
venules were defined as a diameter of 25–35 μm, no
more than 5 adherent leukocytes per 100 μm vessel
length, no blood flow stasis, no lymph vessels or mesen-
terial fat tissue in the immediate vicinity of the observed
vessel segment and at least one free vessel wall without
concomitant or branching vessels.
In total 16 venules in the NaCl (i), 17 venules in the
CDP-choline (ii), 22 venules in the CDP-choline (iii), 23
venules in the CDP-choline (iv), and 17 venules in the
LPS (vi) groups fulfilled the criteria stated above and
were recorded and analyzed.
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Fig. 1 Experimental protocol. Intravital microscopic measurements (IVM) were performed at 0-, 60-, and 120- min in endotoxemic and
nonendotoxemic animals following a stabilization period after surgical preparation. LPS (4 mg/kg/h) or an equivalent volume of saline was
continuously infused starting directly after baseline IVM at 0 min. CDP-choline (100 mg/kg) was applied as an i.v. bolus in treatment groups. All
administered fluids were calculated to guarantee that all animals received equal amounts of intravenous fluids. The color and number code of
the experimental groups introduced in this figure is used in all other figures
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Statistical analysis
The main outcome parameter for this study was the
perivenular macromolecular leakage around postcapil-
lary venules. To evaluate the effect of CDP-choline on
microvascular alterations during endotoxemia, all IVM-
generated microvascular data are compared to the LPS
group unless otherwise stated. The D'Agostino & Pear-
son omnibus normality test was applied to check for
normal distribution. Due to nonparametric data distribu-
tion, nonparametric methods for evaluation were used
(Wilcoxon test for differences within groups and Dunn's
multiple comparisons test for differences between
groups with multiplicity adjusted p values). Data were
considered statistically significant at p < 0.05.
The results are presented in Tables 1, 2, 3 as median
with interquartile range (Q1–Q3). Significant adjusted
p-values of the comparisons with the LPS group and sig-
nificant p-values of the comparisons with the baseline
IVM measurement at 0 min are included in the tables.
Statistical analysis was performed using GraphPad
Prism version 6.0 for Mac OS X, GraphPad Software,
San Diego California USA, www.graphpad.com.
Results
Macromolecular leakage
The baseline IVM measurement at 0 min revealed no
significant differences in macromolecular leakage be-
tween all experimental groups. Macromolecular leakage
increased significantly in all groups over 120 min com-
pared to the respective baseline measurements with the
highest rise of plasma extravasation in the LPS (v) group.
Infusion of LPS (v) caused a significant increase in
macromolecular leakage compared to the NaCl (i) group
at 60 and 120 min. After 120 min all groups treated
with CDP-choline showed a significantly reduced
macromolecular leakage compared to the LPS (v) group.
Table 1 summarizes the results of the IVM measurements
of macromolecular leakage. Figure 2 illustrates the
Table 1 Summarized results of macromolecular leakage
Time after induction of endotoxemia
0 min 60 min 120 min
Macromolecular leakage
[arbitrary units]
Median IQR (Q1-Q3) * Median IQR (Q1-Q3) *1 #2 Median IQR (Q1-Q3) * #
NaCI (i) 0.075 0.05-0.09 ns3 0.15 0.11-0.2 <0.0001 0.0002 0.22 0.14-0.29 <0.0001 <0.0001
CDP-choline prior to NaCI (ii) 0.067 0.05-0.09 ns 0.11 0.07-0.21 <0.0001 0.0054 0.21 0.08-0.36 <0.0001 0.0008
CDP-choline prior to LPS (iii) 0.095 0.07-0.12 ns 0.24 0.12-0.42 0.0141 <0.0001 0.35 0.15-0.51 0.0019 <0.0001
CDP-choline after LPS (iv) 0.095 0.06-0.12 ns 0.27 0.18-0.47 ns <0.0001 0.34 0.25-0.49 0.0022 <0.0001
LPS (v) 0.099 0.07-0.11 0.48 0.34-0.63 <0.0001 0.6 0.51-0.71 <0.0001
1 * significant adjusted p value vs. LPS (v)
2 # significant p value vs. 0 min
3 ns: not significant
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Fig. 2 Effect of CDP-choline administration on macromolecular leakage during endotoxemia. Macromolecular leakage is expressed as ratio of
perivenular to venular fluorescence intensity in arbitrary units. CDP-choline reduced microvascular permeability in postcapillary venules during
endotoxemia. These results indicate that CDP-choline has a protective effect on microvascular permeability. Scatterplots with medians are
displayed. *Significant difference vs. LPS (v). Medians with interquartile range (Q1–Q3) and p values are presented in Table 1
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observed effect of CDP-choline on macromolecular
leakage and displays the significant differences to the
LPS (v) group. Representative IVM images are shown
in Fig. 3.
Leukocyte adherence
No significant differences were observed between all
groups at the beginning of the experiment. The number
of adhering leukocytes increased significantly over
120 min in all LPS treated groups (iii, iv, v) when com-
pared to the respective baseline measurement. Leukocyte
adhesion was significantly increased in the LPS group at
60 and 120 min compared to the NaCl (i) group and
after 120 min compared to the nonendotoxemic CDP-
choline (ii) group. No significant difference between the
LPS (v) group and the endotoxemic CDP-choline (iii, iv)
groups was observed during the experiment. CDP-
choline administration without endotoxemia (ii) did not
result in a significant increase in adhering leukocytes. In
endotoxemic animals treated with CDP-choline (iii, iv)
leukocyte adherence increased significantly compared to
the baseline measurement during the experiment. Table 2
shows the summarized numbers of adherent leukocytes.
Figure 4 illustrates the observed effect of CDP-choline
leukocyte adhesion and displays the significant differ-
ences to the LPS (v) group.
Table 2 Summarized numbers of adherent leukocytes
Time after induction of endotoxemia
0 min 60 min 120 min
Adherent leukocytes [cells/ mm2] Median IQR (Q1-Q3) * Median IQR (Q1-Q3) *1 #2 Median IQR (Q1-Q3) * #
NaCI (i) 140 59-218 ns3 172 85-201 0.0139 ns 136 74-216 <0.0001 ns
CDP-choline prior to NaCI (ii) 206 75-268 ns 204 108-251 ns ns 220 147-337 0.015 ns
CDP-choline prior to LPS (iii) 204 165-250 ns 243 169-375 ns 0.0175 322 234-423 ns <0.0001
CDP-choline after LPS (iv) 239 128-271 ns 305 232-351 ns <0.0001 342 226-418 ns 0.0003
LPS (v) 193 118-280 267 193-358 0.0038 403 224-562 <0.0001
1 * significant adjusted p value vs. LPS (v)
2 # significant p value vs. 0 min
3 ns: not significant
Table 3 Summarized macro- and microhemodynamic parameters
Time after induction of endotoxemia
0 min 60 min 120 min
Mean arterial pressure [mmHg] Median IQR (Q1-Q3) * Median IQR (Q1-Q3) *1 #2 Median IQR (Q1-Q3) * #
NaCI (i) 117 100-126 ns3 131 125-137 0.0037 ns 133 118-145 0.0386 ns
CDP-choline prior to NaCI (ii) 108 101-118 ns 117 93-132 ns ns 133 104-139 ns ns
CDP-choline prior to LPS (iii) 105 97-123 ns 105 101-114 ns ns 113 60-117 ns ns
CDP-choline after LPS (iv) 106 94-120 ns 105 89-120 ns ns 114 100-122 ns ns
LPS (v) 103 89-109 99 89-104 ns 106 97-112 ns
Heart rate [min−1] Median IQR (Q1-Q3) * Median IQR (Q1-Q3) * # Median IQR (Q1-Q3) * #
NaCI (i) 322 317-344 ns 371 332-403 0.0037 0.0002 395 326-441 0.0327 <0.0001
CDP-choline prior to NaCI (ii) 358 338-411 ns 408 400-473 ns 0.0313 433 428-470 ns 0.0313
CDP-choline prior to LPS (iii) 375 351-456 ns 475 447-566 ns 0.0156 449 441-493 ns 0.0313
CDP-choline after LPS (iv) 353 287-380 ns 381 326-432 ns 0.0117 445 358-476 ns 0.0039
LPS (v) 340 320-353 410 391-436 0.0078 491 435-516 0.0078
Venular wall shear rate [s−1] Median IQR (Q1-Q3) * Median IQR (Q1-Q3) * # Median IQR (Q1-Q3) * #
NaCI (i) 400 352-575 ns 505 413-642 ns 0.0006 444 368-573 ns ns
CDP-choline prior to NaCI (ii) 550 427-653 ns 420 356-614 ns ns 302 230-631 ns 0.0395
CDP-choline prior to LPS (iii) 436 367-567 ns 362 274-553 ns 0.0229 311 120-497 ns 0.0009
CDP-choline after LPS (iv) 503 407-582 ns 397 321-505 ns 0.0301 443 281-590 ns 0.0254
LPS (v) 499 405-622 378 251-523 ns 348 285-493 0.0026
1 * significant adjusted p value vs. LPS (v)
2 # significant p value vs. 0 min
3 ns: not significant
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Macro- and microhemodynamic changes
There were no significant differences between all groups
in the macro- and microhemodynamic parameters at the
beginning of the experiment. The mean arterial pressure
differed significantly between the NaCl (i) - and LPS (v)
group at 60 min and at 120 min. No significant
change in mean arterial pressure was observed within
the groups. All groups showed a significant increase
in heart rate over 120 min compared to the baseline
measurement. Venular wall shear rate decreased sig-
nificantly within the LPS group over 120 min. The
venular wall shear rate decreased significantly after
120 min within all CDP-choline groups. The observed
macro- and microhemodynamic changes are summarized
in Table 3 including the significant changes com-
pared to the IVM measurement at 0 min and to the
LPS (v) group.
Discussion
This study examined the effect of Cytidine-5-
diphosphocholine (CDP-choline) on microcirculatory
alterations during endotoxemia. LPS administration sig-
nificantly increased microvascular permeability and
leukocyte adherence and decreased venular wall shear
rate in postcapillary venules. CDP-choline significantly
reduced macromolecular leakage when applied before
and after the start of the LPS infusion. In endotoxemic
animals CDP-choline did not affect the number of
Fig. 3 IVM images demonstrating the CDP-choline effect on microvascular permeability during endotoxemia. Fluorescent IVM images show
postcapillary venules recorded at 0 min (upper panels) and 120 min after the treatment (lower panels). LPS administration alone (v) induces
distinctive macromolecular leakage compared to the baseline measurement at 0 min and to the NaCl group (i). Note the effect of CDP-choline
on reducing macromolecular leakage in endotoxemic animals (iii, iv) compared to the LPS group (v)
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Fig. 4 Effect of CDP-choline administration on leukocyte adherence during endotoxemia. CDP-choline had no effect on the number of adhering
leukocytes during endotoxemia. Scatterplots with medians are displayed. * Significant difference vs. LPS (v). Medians with interquartile range
(Q1–Q3) and p values are presented in Table 2
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adherent leukocytes and the reduced venular wall shear
rate observed after LPS treatment.
The key result of this study is that CDP-choline has a
protective effect on microvascular permeability during
experimental endotoxemia.
Non-neuronal cholinergic mechanisms are fundamental
processes for the fine-tuning of endothelial hemoeostasis
[13]. Both direct and indirect cholinergic stimulation ex-
hibit anti-inflammatory effects on endothelial activation
and leucocyte-endothelial interactions [3, 4, 14]. Proin-
flammatory endothelial cell activation can be suppressed
by the activation of specific nicotinic acetylcholine recep-
tors like the α7nAChR [15] associated with the cho-
linergic anti-inflammatory pathway [5, 6, 16]. CDP-
choline had a protective effect on microvascular bar-
rier function when applied before and after the onset
of endotoxemia in this study. Intravenous administra-
tion of CDP-choline increases plasma and brain cho-
line and acetylcholine levels in rats [17, 18]. Choline
as a selective natural α7nAChR agonist improves sur-
vival in experimental sepsis [19]. Gurun et al. demon-
strated that localized administration of CDP-choline
reduced tissue edema and TNF-α production in a
α7nAChR-dependent mechanism [11]. Moreover activa-
tion of central cholinergic transmission by CDP-choline
has protective α7nAChR- independent effects on myocar-
dial ischemia-reperfusion damage [18].
The observed protective effect of CDP-choline on
microvascular permeability is therefore probably attrib-
utable to a cholinergic activation of endothelial cells that
could be directly mediated by α7nAChR on a cellular
level or by central anti-inflammatory cholinergic signals.
This protective effect is in line with scientific evidence re-
garding the anti-inflammatory potential of CDP-choline in
other experimental settings [20–23].
There is ample evidence for interdependent leukocyte-
dependent and leukocyte-independent mechanisms af-
fecting endothelial permeability [12, 24]. Leukocyte
recruitment can be blocked by α7nAChR-dependent
cell activation [3].
In contrast to the effect of the centrally acting acetyl-
cholinesterase inhibitor physostigmine, which reduced
leukocyte adherence [4], CDP choline did not affect
leukocyte adhesion during endotoxemia. This could
indicate that leukocyte activation is more affected by
centrally mediated cholinesterase inhibition or by more
effectively elevating ACh serum levels. CDP-choline and
choline are α7nAChR agonists with a lower potency as
ACh, possibly explaining the missing effect on the num-
bers of adherent leukocytes observed in this study. LPS
causes shedding of the endothelial glycocalix in rats [25],
and inhibition of glycocalyx shedding reduces leukocyte-
endothelial adhesion [26]. Increased microvascular perme-
ability due to a breakdown of the endothelial glycocalix
results in an increased transcapillary escape rate of albu-
min in experimental sepsis [27]. The decreased macro-
molecular leakage of FITC-albumin in the endotoxemic
CDP-choline treated groups could be interpreted as a
stabilization of the endothelial surface layer. A modulation
of glycocalix function influencing the interaction between
endothelial cells and leukocytes could be an explanation
for the observed protective effect of CDP-choline on
microvascular permeability paralleled by increased num-
bers of adherent leukocytes in the CDP-choline treated
endotoxemic groups. Further studies focusing on qualita-
tive effects of CDP-choline on leukocyte-endothelial inter-
actions and glycocalix function are required to evaluate
the in vivo findings of this study. The increased leukocyte
adherence in LPS-treated animals is consistent with the
decreased venular wall shear rate induced by endotoxemia
[28]. Venular wall shear rate decreased significantly in all
CDP-choline treated groups. Interestingly the largest de-
crease in venular wall shear rate was observed within the
nonendotoxemic CDP-choline treated group indicating a
direct effect of CDP-choline on the microcirculation with-
out causing increased microvascular permeability and
leukocyte adherence. In LPS treated animals CDP-choline
treatment had no distinguishable effect on venular wall
shear rate. Microvascular flow is impaired during early
sepsis and uncoupled from macrovascular function [28].
This uncoupling is clearly demonstrated by the
hemodynamic profile of the LPS (v) group. Macrohemo-
dynamic parameters were not distinguishably affected by
CDP-choline treatment. It has been demonstrated that
CDP-choline restores renal and mesenteric arterial blood
flow and hypotension in shock states and prevents death
in myocardial ischaemia–reperfusion injury by activating
central cholinergic neurotransmission [17, 18, 29]. This in-
dicates that CDP-choline has positive effects on a compro-
mised circulatory system. We did not induce an
endotoxemic shock during the 120 min observation
time of this study therefore no final conclusion can
be drawn regarding the hemodynamic effects of CDP-
choline. Given the heterogeneity of microcirculatory per-
fusion during sepsis, microvascular changes in the mesen-
teric postcapillary venules examined may not reflect the
microcirculatory situation in other vascular beds. There-
fore further studies to evaluate the hemodynamic and
microcirculatory effects of CDP-choline during sepsis re-
main to be done.
Limitations
We could not quantify plasma cytokines and glycocalyx
marker in blood serum samples of the experimental ani-
mals due to the interference of the fluorescent dyes used
for IVM with the standardized ELISA technology.
Therefore, no direct correlation between our IVM re-
sults and the effect of CDP-choline on the systemic
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inflammatory response and the degree of glycocalyx
shedding could be drawn.
Conclusion
CDP-choline was effective in reducing LPS-induced micro-
vascular permeability in endotoxemic rats. Leukocyte
adherence and venular wall shear rate were not affected by
CDP-choline during endotoxemia. Regarding the effect of
CDP-choline on leukocyte-endothel interactions and
microcirculatory alterations in this study, no final conclu-
sion can be drawn necessitating further studies.
The protective effect on microvascular permeability of
CDP-choline in this study may carefully be used as a
basis for a clinical approach to stabilize capillary leakage
in human sepsis. CDP-choline has been thoroughly stud-
ied in clinical trials for its brain protective properties on
cerebrovascular and neurodegenerative diseases with an
excellent drug safety profile [8–10, 30]. Considering its
anti-inflammatory efficacy CDP-choline is a substance
with great potential for clinical sepsis treatment.
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